Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Cancer Metastatic × abemaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Neoplasm Metastasis 7 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 3 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Neuroblastoma 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Head and Neck Neoplasms 2 Glioma 2 Glioblastoma 2 Diffuse Intrinsic Pontine Glioma 2 Brain Neoplasms 2 Advanced Cancer 2 Urologic Neoplasms 1 Unilateral Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Multiple Myeloma 1 Metastatic Castration-Resistant Prostate Cancer 1 Mesothelioma, Malignant 1 Mesothelioma 1

Interventions

Letrozole 3 exemestane 2 Fulvestrant 2 Anastrozole 2 ribociclib 1 irinotecan sucrosofate 1 abemaciclib 1 Paclitaxel 1 Liposomes 1 Irinotecan 1 Everolimus 1 Cyclophosphamide 1 Cell Separation 1 Capecitabine 1 Aromatase Inhibitors 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04603183 2025-12-12

ABIGAIL

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡